



## CD69 Antibody [H1.2F3]

CATALOG NUMBER: 76-817

### Specifications

<b>SPECIES REACTIVITY:</b>	Mouse
<b>TESTED APPLICATIONS:</b>	FACS, Func
<b>USER NOTE:</b>	Optimal dilutions for each application to be determined by the researcher.
<b>SPECIFICITY:</b>	The H1.2F3 monoclonal antibody specifically reacts with human CD69, the 27-33 kDA type II transmembrane protein also known as the very early activation antigen (VEA) or the activation inducer molecule (AIM).
<b>HOST SPECIES:</b>	Hamster

### Properties

<b>PURIFICATION:</b>	The monoclonal antibody was purified utilizing affinity chromatography. The endotoxin level is determined by LAL test to be less than 0.01 EU/μg of the protein.
<b>PHYSICAL STATE:</b>	liquid
<b>BUFFER:</b>	Phosphate-buffered aqueous solution, pH7.2.
<b>CONCENTRATION:</b>	1 mg/mL
<b>STORAGE CONDITIONS:</b>	The product should be stored undiluted at 4°C . Do not freeze.
<b>CLONALITY:</b>	Monoclonal
<b>ISOTYPE:</b>	Armenian Hamster IgG
<b>CONJUGATE:</b>	Unconjugated

### Additional Info

<b>ALTERNATE NAMES:</b>	AIM, VEA, AI452015, 5830438K24Rik, Cd69
<b>OFFICIAL SYMBOL:</b>	Cd69
<b>GENE ID:</b>	12515

### Background

<b>BACKGROUND:</b>	The H1.2F3 monoclonal antibody specifically reacts with human CD69, the 27-33 kDA type II transmembrane protein also known as the very early activation antigen (VEA) or the activation inducer molecule (AIM). It is expressed as a disulfide-linked dimer on B cells, T cells, NK cells, platelets, eosinophils, and neutrophils. It increases in expression upon cell activation and seems to serve a role as a signaling receptor.
<b>REFERENCES:</b>	<p>1) Marzio, R., Jirillo, E., Ransijn, A., Mauel, J., Corradin, S. B. (1997). Expression and function of the early activation antigen CD69 in murine macrophages. <i>Journal of leukocyte biology</i>, 62(3), 349-355.</p> <p>2) Yokoyama, W. M., Koning, F., Kehn, P. J., Pereira, G. M., Stingl, G., Coligan, J. E., Shevach, E. M. (1988). Characterization of a cell surface-expressed disulfide-linked dimer involved in murine T cell activation. <i>The Journal of Immunology</i>, 141(2), 369-376.</p> <p>3) Sobel, E. S., Yokoyama, W. M., Shevach, E. M., Eisenberg, R. A., Cohen, P. L. (1993). Aberrant expression of the very early activation antigen on MRL/Mp-lpr/lpr lymphocytes. <i>The Journal of Immunology</i>, 150(2), 673-682.</p>

**FOR RESEARCH USE ONLY**

